I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) shares fell 1.19% to $62.84 on Thursday, underperforming the broader market and key competitors like Johnson & Johnson and Pfizer. This marks the stock's third consecutive day of losses, leaving it 8.45% below its 52-week high. Trading volume reached 12.1 million, exceeding the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Bristol Myers Squibb Co. (BMY) shed 1.19% to $62.84 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.14% to 7,637.76 and the Dow Jones Industrial Average rising 0.61% to 51,778.04.
This was the stock's third consecutive day of losses.
Bristol Myers Squibb Co. closed 8.45% below its 52-week high of $68.64, which the company achieved on August 19th.
The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 1.10% to $270.22, Pfizer Inc. (PFE) rose 0.66% to $27.64, and Abbott Laboratories (ABT) fell 0.13% to $102.23.
Trading volume (12.1 M) eclipsed its 50-day average volume of 10.1 M.
Data source: Dow Jones Market Data, FactSet. Data compiled September 17, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-17-26 1636ET